Literature DB >> 22595776

Ocular sarcoidosis.

Bahram Bodaghi1, Valérie Touitou, Christine Fardeau, Catherine Chapelon, Phuc LeHoang.   

Abstract

Sarcoidosis, a chronic multisystem disease, is a common cause of ocular inflammation. Even though clinical features are well-established, diagnosis requires histological confirmation, which remains difficult in patients with uveitis. Thus, the frequency of ocular sarcoidosis is overestimated. A set of criteria has been recently established in order to improve the diagnostic procedure. New imaging tools will enable the ophthalmologist to evaluate the level of ocular inflammation and to monitor its resolution after treatment initiation. Indocyanine green angiography and optical coherence tomography have dramatically improved our understanding of choroidal granulomas and macular edema. Treatment is based on topical and systemic corticosteroids in most of the cases, but immuno-suppressive agents may be necessary. The visual outcome remains favorable but severe complications, including glaucoma, cystoid macular edema and choroidal neovascularization, may need a prompt and aggressive management.
Copyright © 2012 Elsevier Masson SAS. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22595776     DOI: 10.1016/j.lpm.2012.04.004

Source DB:  PubMed          Journal:  Presse Med        ISSN: 0755-4982            Impact factor:   1.228


  13 in total

Review 1.  Sarcoidosis of the head and neck.

Authors:  Arvind K Badhey; Sameep Kadakia; Ricardo L Carrau; Codrin Iacob; Azita Khorsandi
Journal:  Head Neck Pathol       Date:  2014-09-03

Review 2.  [Association of the different forms of uveitis with inflammatory rheumatic diseases and their treatment].

Authors:  Nicole Stübiger; Sanaz Farrokhi; Yannik Gkanatsas; Christoph Deuter; Ina Kötter
Journal:  Z Rheumatol       Date:  2022-08-30       Impact factor: 1.530

3.  Choroidal nonperfusion on optical coherence tomography angiography in a case of unilateral posterior segment ocular sarcoidosis misdiagnosed as MEWDS.

Authors:  Emily S Levine; Luísa S M Mendonça; Caroline R Baumal; Adam T Chin; Lana Rifkin; Nadia K Waheed
Journal:  Am J Ophthalmol Case Rep       Date:  2020-09-25

4.  Cistoid macular edema as first manifestation of sarcoidosis.

Authors:  Lucia Cabrillo-Estevez; Lourdes de Juan-Marcos; Danai Kyriakou; Emiliano Hernández-Galilea
Journal:  Int Ophthalmol       Date:  2013-12-10       Impact factor: 2.031

5.  Ranibizumab in choroidal neovascularisation associated with ocular sarcoidosis.

Authors:  Vasileios Efstathios Konidaris; Theodoros Empeslidis
Journal:  BMJ Case Rep       Date:  2013-11-14

Review 6.  T Cell-Mediated Chronic Inflammatory Diseases Are Candidates for Therapeutic Tolerance Induction with Heat Shock Proteins.

Authors:  Ariana Barbera Betancourt; Qingkang Lyu; Femke Broere; Alice Sijts; Victor P M G Rutten; Willem van Eden
Journal:  Front Immunol       Date:  2017-10-26       Impact factor: 7.561

7.  A Comparative Study of Characteristics and Outcomes of Patients with Proved and Suggested Sarcoid Uveitis Occurring after Ophthalmic Procedure.

Authors:  Yvan Jamilloux; Aude Taleb; Audrey De Parisot; Laurent Pérard; Carole Burillon; Christiane Broussolle; Laurent Kodjikian; Pascal Sève
Journal:  J Ophthalmol       Date:  2018-10-18       Impact factor: 1.909

8.  Peripapillary Choroidal Neovascular Membrane Secondary to Sarcoidosis-Related Panuveitis: Treatment with Aflibercept and Ranibizumab with a 50-month Follow-Up.

Authors:  Artemis Matsou; Maria Dermenoudi; Despina Tzetzi; Tryfon Rotsos; Olga Makri; Eleftherios Anastasopoulos; Chrysanthos Symeonidis
Journal:  Case Rep Ophthalmol       Date:  2021-04-12

Review 9.  Profile of adalimumab and its potential in the treatment of uveitis.

Authors:  Stephen J Balevic; C Egla Rabinovich
Journal:  Drug Des Devel Ther       Date:  2016-09-19       Impact factor: 4.162

10.  Association of genetic variants in RAB23 and ANXA11 with uveitis in sarcoidosis.

Authors:  Samaneh Davoudi; Victoria S Chang; Daniel Navarro-Gomez; Lynn K Stanwyck; Damla Duriye Sevgi; Evangelia Papavasileiou; Aiai Ren; Eduardo Uchiyama; Lynn Sullivan; Ann-Marie Lobo; George N Papaliodis; Lucia Sobrin
Journal:  Mol Vis       Date:  2018-01-21       Impact factor: 2.367

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.